Symbols / SNOA Stock $1.11 -2.63% Sonoma Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NCM
SNOA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Ms. Amy M. Trombly Esq., J.D.
Exch · Country NCM · United States
Market Cap 1.93M
Enterprise Value 66.90K
Income -3.37M
Sales 17.72M
FCF (ttm) -3.57M
Book/sh 1.98
Cash/sh 1.48
Employees 8
Insider 10d —
IPO Jan 25, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.98
PEG 1.08
P/S 0.11
P/B 0.56
P/C —
EV/EBITDA -0.03
EV/Sales 0.00
Quick Ratio 1.21
Current Ratio 2.88
Debt/Eq 19.09
LT Debt/Eq —
EPS (ttm) -1.95
EPS next Y -0.56
EPS Growth —
Revenue Growth 22.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-10
Earnings (prior) 2026-02-10
ROA -12.67%
ROE -81.18%
ROIC —
Gross Margin 38.16%
Oper. Margin -15.59%
Profit Margin -19.02%
Shs Outstand 1.74M
Shs Float 1.72M
Insider Own 1.15%
Instit Own 6.29%
Short Float 1.20%
Short Ratio 0.42
Short Interest 16.11K
52W High 6.92
vs 52W High -83.96%
52W Low 0.85
vs 52W Low 30.59%
Beta 1.76
Impl. Vol. —
Rel Volume 3.19
Avg Volume 133.05K
Volume 423.92K
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $12.00
Tgt High $12.00
# Analysts 1
Recom None
Prev Close $1.14
Price $1.11
Change -2.63%
About

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$1.11
Latest analyst target
3. DCF / Fair value
$-36.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.11
Low
$12.00
High
$12.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-09-05 init Ladenburg Thalmann — → Buy $3
2018-03-06 down Maxim Group Buy → Hold —
2017-12-28 init Benchmark — → Speculative Buy $10
2017-11-10 main Maxim Group — → Buy $11
News
RSS: Latest SNOA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-06-20 DAL POGGETTO JOHN Officer — 15,000 $0.00 $0
2024-06-20 DVONCH JEROME J Chief Financial Officer — 53,586 $0.00 $0
2024-06-20 TROMBLY AMY MOSS Chief Executive Officer — 53,586 $0.00 $0
2024-06-20 THORNTON BRUCE Officer — 53,586 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
14.29
+12.19%
12.73
-4.05%
13.27
+5.10%
12.63
Operating Revenue
14.29
+12.19%
12.73
-4.05%
13.27
+5.10%
12.63
Cost Of Revenue
8.82
+10.43%
7.99
-9.15%
8.79
+1.85%
8.63
Reconciled Cost Of Revenue
8.82
+10.43%
7.99
-9.15%
8.79
+1.85%
8.63
Gross Profit
5.46
+15.17%
4.75
+5.99%
4.48
+12.12%
3.99
Operating Expense
9.18
-2.87%
9.45
+4.41%
9.05
-8.43%
9.88
Research And Development
1.81
-3.05%
1.87
+803.86%
0.21
+65.60%
0.12
Selling General And Administration
7.36
-2.83%
7.58
-14.31%
8.84
-9.38%
9.76
Total Expenses
18.00
+3.22%
17.44
-2.28%
17.84
-3.63%
18.52
Operating Income
-3.71
+21.08%
-4.70
-2.87%
-4.57
+22.37%
-5.89
Total Operating Income As Reported
-3.71
+21.08%
-4.70
-2.87%
-4.57
+22.37%
-5.89
EBITDA
-3.57
+21.06%
-4.53
-1.80%
-4.45
+22.03%
-5.70
Normalized EBITDA
-3.57
+21.06%
-4.53
-1.80%
-4.45
+32.39%
-6.57
Reconciled Depreciation
0.14
-21.59%
0.18
+40.80%
0.12
-32.80%
0.19
EBIT
-3.71
+21.08%
-4.70
-2.87%
-4.57
+22.37%
-5.89
Total Unusual Items
—
—
0.00
-99.89%
0.87
Total Unusual Items Excluding Goodwill
—
—
0.00
-99.89%
0.87
Special Income Charges
—
—
0.00
-99.89%
0.87
Other Special Charges
—
—
—
-0.72
Net Income
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Pretax Income
-2.91
+42.22%
-5.03
+2.95%
-5.18
+4.32%
-5.42
Net Non Operating Interest Income Expense
—
—
0.02
+260.00%
-0.01
Net Interest Income
—
—
0.02
+260.00%
-0.01
Other Income Expense
0.80
+343.33%
-0.33
+46.25%
-0.61
-228.18%
0.48
Other Non Operating Income Expenses
0.80
+343.33%
-0.33
+46.25%
-0.61
-55.84%
-0.39
Tax Provision
0.55
+380.61%
-0.20
-493.94%
-0.03
+90.06%
-0.33
Tax Rate For Calcs
0.00
+425.00%
0.00
+566.67%
0.00
-90.32%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
-100.00%
0.05
Net Income Including Noncontrolling Interests
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Net Income From Continuing Operation Net Minority Interest
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Net Income From Continuing And Discontinued Operation
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Net Income Continuous Operations
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Net Income Discontinuous Operations
—
—
—
0.00
Normalized Income
-3.46
+28.50%
-4.83
+6.13%
-5.15
+12.77%
-5.90
Net Income Common Stockholders
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Diluted EPS
-2.79
+73.75%
-10.63
+65.03%
-30.40
+20.83%
-38.40
Basic EPS
-2.79
+73.75%
-10.63
+65.03%
-30.40
+20.83%
-38.40
Basic Average Shares
1.24
+172.75%
0.46
+168.12%
0.17
+27.93%
0.13
Diluted Average Shares
1.24
+172.75%
0.46
+168.12%
0.17
+27.93%
0.13
Diluted NI Availto Com Stockholders
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Gain On Sale Of PPE
—
—
0.00
-99.33%
0.15
Total Other Finance Cost
—
—
-0.02
-260.00%
0.01
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
13.69
-7.10%
14.74
-9.19%
16.23
-13.87%
18.84
Current Assets
12.65
+0.80%
12.55
-9.06%
13.80
-16.02%
16.43
Cash Cash Equivalents And Short Term Investments
5.37
+71.80%
3.13
-18.12%
3.82
-48.35%
7.40
Cash And Cash Equivalents
5.37
+71.80%
3.13
-18.12%
3.82
-48.35%
7.40
Receivables
3.76
-37.22%
5.99
-6.59%
6.42
+34.30%
4.78
Accounts Receivable
2.23
-22.98%
2.90
+12.67%
2.57
+6.86%
2.41
Gross Accounts Receivable
2.24
-23.42%
2.92
+13.02%
2.59
+4.02%
2.49
Allowance For Doubtful Accounts Receivable
-0.01
+70.37%
-0.03
-68.75%
-0.02
+80.25%
-0.08
Taxes Receivable
1.53
-50.55%
3.10
-19.48%
3.85
+62.17%
2.37
Inventory
2.92
+7.21%
2.72
-4.86%
2.86
+7.32%
2.66
Raw Materials
1.40
-22.59%
1.80
+2.15%
1.76
+8.49%
1.63
Finished Goods
1.82
+49.88%
1.21
-8.80%
1.33
+28.25%
1.04
Prepaid Assets
0.24
-30.59%
0.34
-22.37%
0.44
-41.99%
0.76
Current Deferred Assets
0.21
-19.08%
0.26
+9.17%
0.24
+10.09%
0.22
Other Current Assets
0.15
+40.95%
0.10
+320.00%
0.03
-95.97%
0.62
Total Non Current Assets
1.04
-52.33%
2.19
-9.91%
2.43
+0.75%
2.42
Net PPE
0.31
-52.53%
0.65
-28.15%
0.91
+3.07%
0.88
Gross PPE
2.38
-21.35%
3.03
+3.80%
2.92
+12.74%
2.59
Accumulated Depreciation
-2.08
+12.82%
-2.38
-18.17%
-2.01
-17.71%
-1.71
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.34
-7.14%
0.36
+12.35%
0.32
+31.17%
0.25
Other Properties
1.55
-24.59%
2.06
+0.98%
2.04
+10.98%
1.84
Leases
0.49
-18.84%
0.60
+9.21%
0.55
+10.14%
0.50
Non Current Deferred Assets
0.66
-55.12%
1.48
+1.44%
1.45
-0.34%
1.46
Non Current Deferred Taxes Assets
0.59
-48.56%
1.15
+20.65%
0.95
+14.48%
0.83
Other Non Current Assets
0.07
+12.12%
0.07
-9.59%
0.07
-5.19%
0.08
Total Liabilities Net Minority Interest
9.28
+7.89%
8.60
+4.23%
8.25
-18.66%
10.15
Current Liabilities
4.10
+10.14%
3.72
+0.05%
3.72
-36.12%
5.82
Payables And Accrued Expenses
2.69
+32.77%
2.03
-12.07%
2.30
-14.67%
2.70
Payables
0.95
+57.00%
0.61
-27.82%
0.84
-48.75%
1.64
Accounts Payable
0.95
+57.00%
0.61
-27.82%
0.84
-48.75%
1.64
Current Accrued Expenses
1.74
+22.41%
1.42
-3.01%
1.46
+38.15%
1.06
Current Debt And Capital Lease Obligation
0.28
-46.64%
0.52
-24.16%
0.69
-35.07%
1.06
Current Debt
0.22
-31.89%
0.32
-25.06%
0.43
-46.66%
0.81
Other Current Borrowings
—
0.32
-25.06%
0.43
-46.66%
0.81
Current Capital Lease Obligation
0.06
-70.71%
0.20
-22.66%
0.26
+2.40%
0.25
Current Deferred Liabilities
0.64
+34.10%
0.48
+198.75%
0.16
-87.47%
1.28
Current Deferred Revenue
0.64
+34.10%
0.48
+198.75%
0.16
-87.47%
1.28
Other Current Liabilities
0.49
-29.83%
0.69
+22.61%
0.57
-27.81%
0.78
Total Non Current Liabilities Net Minority Interest
5.19
+6.18%
4.88
+7.65%
4.54
+4.80%
4.33
Long Term Debt And Capital Lease Obligation
0.03
-68.97%
0.09
-46.30%
0.16
-47.57%
0.31
Long Term Capital Lease Obligation
0.03
-68.97%
0.09
-46.30%
0.16
-47.57%
0.31
Tradeand Other Payables Non Current
5.14
+9.17%
4.71
+11.22%
4.24
+10.34%
3.84
Non Current Deferred Liabilities
0.02
-80.46%
0.09
-37.86%
0.14
-23.08%
0.18
Non Current Deferred Revenue
0.02
-80.46%
0.09
-37.86%
0.14
-23.08%
0.18
Stockholders Equity
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Common Stock Equity
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Capital Stock
0.00
0.00
-100.00%
0.01
+150.00%
0.00
Common Stock
0.00
0.00
-100.00%
0.01
+150.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
1.63
+109.42%
0.78
+216.35%
0.25
+59.10%
0.16
Ordinary Shares Number
1.63
+109.42%
0.78
+216.35%
0.25
+59.10%
0.16
Additional Paid In Capital
206.59
+1.67%
203.21
+1.15%
200.90
+1.79%
197.37
Retained Earnings
-197.81
-1.78%
-194.35
-2.55%
-189.51
-2.79%
-184.36
Gains Losses Not Affecting Retained Earnings
-4.38
-60.71%
-2.72
+20.33%
-3.42
+20.73%
-4.31
Total Equity Gross Minority Interest
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Total Capitalization
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Working Capital
8.55
-3.14%
8.83
-12.42%
10.08
-4.99%
10.61
Invested Capital
4.63
-28.31%
6.46
-23.17%
8.41
-11.54%
9.51
Total Debt
0.30
-49.84%
0.61
-28.39%
0.85
-37.89%
1.37
Capital Lease Obligations
0.09
-70.18%
0.28
-31.82%
0.42
-25.22%
0.56
Net Tangible Assets
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Tangible Book Value
4.41
-28.12%
6.14
-23.07%
7.98
-8.28%
8.70
Current Notes Payable
0.22
-31.89%
0.32
-25.06%
0.43
—
Inventories Adjustments Allowances
-0.30
-0.68%
-0.30
-25.42%
-0.24
—
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-0.09
+96.33%
-2.40
+61.02%
-6.15
-44.82%
-4.25
Cash Flow From Continuing Operating Activities
-0.09
+96.33%
-2.40
+61.02%
-6.15
-44.82%
-4.25
Net Income From Continuing Operations
-3.46
+28.50%
-4.83
+6.13%
-5.15
-1.28%
-5.09
Depreciation Amortization Depletion
0.14
-21.59%
0.18
+40.80%
0.12
-32.80%
0.19
Depreciation
0.14
-21.59%
0.18
+40.80%
0.12
-32.80%
0.19
Depreciation And Amortization
0.14
-21.59%
0.18
+40.80%
0.12
-32.80%
0.19
Other Non Cash Items
0.17
+8.07%
0.16
-6.94%
0.17
-22.42%
0.22
Stock Based Compensation
0.22
-56.59%
0.52
-22.87%
0.67
+75.13%
0.38
Provisionand Write Offof Assets
—
—
-0.07
+95.69%
-1.53
Deferred Tax
0.36
+427.52%
-0.11
-194.59%
-0.04
+95.54%
-0.83
Deferred Income Tax
0.36
+427.52%
-0.11
-194.59%
-0.04
+95.54%
-0.83
Operating Gains Losses
—
—
-0.00
+99.86%
-0.72
Change In Working Capital
2.48
+46.25%
1.69
+187.72%
-1.93
-161.64%
3.13
Change In Receivables
0.43
+288.70%
-0.23
-5650.00%
-0.00
-100.20%
1.97
Changes In Account Receivables
0.43
+288.70%
-0.23
-5650.00%
-0.00
-100.20%
1.97
Change In Inventory
-0.39
-310.87%
0.18
0.00
+100.00%
-0.10
Change In Prepaid Assets
1.09
-1.90%
1.11
+461.76%
-0.31
+33.48%
-0.46
Change In Payables And Accrued Expense
1.14
+429.17%
0.22
+163.34%
-0.34
-138.66%
0.88
Change In Accrued Expense
0.29
+1452.63%
0.02
-85.04%
0.13
-81.30%
0.68
Change In Payable
0.85
+330.46%
0.20
+142.09%
-0.47
-330.54%
0.20
Change In Account Payable
0.42
+249.64%
-0.28
+67.82%
-0.86
-450.32%
-0.16
Change In Other Working Capital
0.38
-35.01%
0.58
+152.17%
-1.11
-204.34%
1.06
Change In Other Current Liabilities
-0.17
-8.07%
-0.16
+6.94%
-0.17
+22.07%
-0.22
Investing Cash Flow
-0.08
-3900.00%
-0.00
+99.22%
-0.26
-160.61%
-0.10
Cash Flow From Continuing Investing Activities
-0.08
-3900.00%
-0.00
+99.22%
-0.26
-160.61%
-0.10
Net PPE Purchase And Sale
-0.08
-3900.00%
-0.00
+99.26%
-0.27
-96.35%
-0.14
Purchase Of PPE
-0.08
-3900.00%
-0.00
+99.26%
-0.27
-96.35%
-0.14
Capital Expenditure
-0.08
-3900.00%
-0.00
+99.26%
-0.27
-96.35%
-0.14
Net Intangibles Purchase And Sale
—
—
—
0.00
Net Other Investing Changes
—
0.01
+36.36%
0.01
-71.05%
0.04
Financing Cash Flow
3.03
+80.79%
1.68
-32.66%
2.49
-66.35%
7.40
Cash Flow From Continuing Financing Activities
3.03
+80.79%
1.68
-32.66%
2.49
-66.35%
7.40
Net Issuance Payments Of Debt
-0.40
+16.01%
-0.48
+46.20%
-0.89
-139.04%
-0.37
Issuance Of Debt
—
—
0.52
+318.70%
0.12
Repayment Of Debt
-0.40
+16.01%
-0.48
+46.20%
-0.89
-79.88%
-0.50
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
+100.00%
-0.12
+74.30%
-0.47
Net Long Term Debt Issuance
—
0.00
+100.00%
-0.12
+74.30%
-0.47
Short Term Debt Issuance
—
—
0.52
+318.70%
0.12
Short Term Debt Payments
-0.40
+16.01%
-0.48
+37.86%
-0.77
-55.73%
-0.50
Net Short Term Debt Issuance
-0.40
+16.01%
-0.48
+37.86%
-0.77
-106.95%
-0.37
Net Common Stock Issuance
3.08
+72.53%
1.78
-37.80%
2.87
-62.03%
7.55
Common Stock Payments
-0.00
0.00
—
—
Repurchase Of Capital Stock
-0.00
0.00
—
—
Proceeds From Stock Option Exercised
0.08
0.00
0.00
-100.00%
0.22
Net Other Financing Charges
0.27
-26.54%
0.37
-27.57%
0.52
—
Changes In Cash
2.86
+495.30%
-0.72
+81.54%
-3.92
-228.60%
3.05
Effect Of Exchange Rate Changes
-0.62
-2025.00%
0.03
-90.72%
0.34
+171.65%
0.13
Beginning Cash Position
3.13
-18.12%
3.82
-48.35%
7.40
+75.26%
4.22
End Cash Position
5.37
+71.80%
3.13
-18.12%
3.82
-48.35%
7.40
Free Cash Flow
-0.17
+93.00%
-2.40
+62.62%
-6.42
-46.43%
-4.38
Interest Paid Supplemental Data
0.01
-50.00%
0.02
+29.41%
0.02
-29.17%
0.02
Income Tax Paid Supplemental Data
—
—
0.00
-100.00%
0.77
Change In Income Tax Payable
0.43
-9.05%
0.47
+19.95%
0.40
+10.00%
0.36
Change In Tax Payable
0.43
-9.05%
0.47
+19.95%
0.40
+10.00%
0.36
Common Stock Issuance
3.08
+72.59%
1.78
-37.80%
2.87
-62.03%
7.55
Issuance Of Capital Stock
3.08
+72.59%
1.78
-37.80%
2.87
-62.03%
7.55
Sale Of Intangibles
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category